Pharming Group (NASDAQ:PHAR) has nominated Fabrice Chouraqui as its new Executive Director and CEO, succeeding Sijmen de Vries. The appointment will be for a four-year term, subject to shareholder ...
A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate ...
ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...
This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...
Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).
(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...
Novartis’ targeted factor B inhibitor iptacopan ... haematopoietic cell transplantation at City of Hope in California, USA.
Explore Novartis stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for NVS. Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results